Shares of Puma Biotechnology soared more than 220% after the markets closed on Tuesday as investors cheered the biotech’s positive Phase III numbers for a late-stage study of their lead drug neratinib (PB272).

…read more

Source: Puma shares triple on positive PhIII neratinib data, plans to file for approval


0 No comments